

Form PTO-1449 (modified)

Atty. Docket No.  
UTSB:721USSerial No.  
10/620,049

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant  
Barrett R. Harvey *et al.*Filing Date:  
July 15, 2003Gr up:  
1653U.S. Patent Documents  
See Page 1Foreign Patent Documents  
See Page 1Other Art  
See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
<i>MA</i>	A1	5,601,823 A	2/11/1997	Williams <i>et al.</i>	424	167.1	12/02/93
<i>MA</i>	A2	6,329,156 B1	12/11/01	Cirino <i>et al.</i>	435	7.21	03/22/99

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
<i>MA</i>	B1	WO 99/36569	01/20/99	PCT			

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>MA</i>	C1	Bradley <i>et al.</i> , <i>Nature</i> , "Identification of the cellular receptor for anthrax toxin," 8;414(6860):225-229, 2001.
	C2	Bull and Parrich, "A binding contract for anthrax," <i>Science</i> , 297:201-202, 2002.
	C3	Chen and Okayama, "High-efficiency transformation of mammalian cells by plasmid DNA," <i>Mol. Cell Biol.</i> , 7(8):2745-2752, 1987.
	C4	Chen <i>et al.</i> , "Isolation of high-affinity ligand-binding proteins by periplasmic expression with cyto metric screening," <i>Nat. Biotechnol.</i> , 19:537-542, 2001.
	C5	Chen <i>et al.</i> , "In vitro scanning saturation mutagenesis of all the specificity determining residues in an antibody binding site," <i>Protein Eng.</i> , 12:349-356, 1999.
	C6	Daughterty <i>et al.</i> , "Quantitative analysis of the effect of the mutation frequency on the affinity maturation of antibodies," <i>Proc. Natl. Acad. Sci., USA</i> , 97:2029-2034, 2000.
	C7	Ezzell <i>et al.</i> , "Immunoelectrophoretic analysis, toxicity, and kinetics of in vitro production of the protective antigen and lethal factor components of <i>Bacillus anthracis</i> toxin," <i>Infect. Immun.</i> , 45:761-777, 1984.
	C8	Georgiou <i>et al.</i> , "Display of heterologous proteins on the surface of microorganisms: from the screening of combinatorial libraries to live recombinant vaccines," <i>Nat. Biotechnol.</i> , 15:29-34, 1997.

25326162.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

UTSB:721US

Serial No.

10/620,049

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Barrett R. Harvey *et al.*

Filing Date:

July 15, 2003

Gr up:

1653

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
24	C9	Hayhurst and Georgiou, "High throughput isolation," <i>Curr. Opin. Chem. Biol.</i> , 5:683-689, 2001.
	C10	Hayhurst and Harris, "Escherichia coli Skp chaperone coexpression improves solubility and phage display of single-chain antibody fragments," <i>Protein Expr. Purif.</i> , 15:336-343, 1999.
	C11	Hayhurst <i>et al.</i> , "Isolation and expression of recombinant antibody fragments to the biological warfare pathogen <i>Brucella melitensis</i> ," <i>J. Immunol. Methods</i> , 276:185-196, 2003.
	C12	Hayhurst, "Improved expression characteristics of single-chain Fv fragments when fused downstream of the Escherichia coli maltose-binding protein or upstream of a single immunoglobulin-constant domain," <i>Protein Expr. Purif.</i> , 18:1-10, 2000.
	C13	Hoess, "Protein design and phage display," <i>Chem. Rev.</i> , 101:3205-3218, 2001
	C14	Ivins <i>et al.</i> , "Influence of body weight on response of Fischer 344 rats to anthrax lethal toxin," <i>Applies and Environmental Microbiology</i> , 55:2098-2100, 1989.
	C15	Keller and Stiehm, "Passive immunity in prevention and treatment of infectious diseases," <i>Clin. Microbiol. Reviews</i> , 13:602-614, 2000.
	C16	Krebber <i>et al.</i> , "Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system," <i>J. Immunol. Methods</i> , 201:35-55, 1997.
	C17	Leppla, "Anthrax toxin," Chapter 19 In: <i>Handbook of Experimental Pharmacology</i> , 145:445-472, 2000.
	C18	Li <i>et al.</i> , "X-ray snapshots of the maturation of an antibody response to a protein antigen," <i>Nat. Struct. Biol.</i> , 10(6):482-488, 2003.
	C19	Little <i>et al.</i> , "Characterization of lethal factor binding and cell receptor binding domains of protective antigen of <i>Bacillus anthracis</i> using monoclonal antibodies," <i>Microbiology</i> , 142:707-715, 1996.
	C20	Little <i>et al.</i> , "Passive protection by polyclonal antibodies against <i>Bacillus anthracis</i> infection in guinea pigs," <i>Infection and Immunity</i> , 65:5171-5175, 1997.
	C21	Little <i>et al.</i> , "Production and characterization of monoclonal antibodies to the protective antigen component of <i>Bacillus anthracis</i> toxin," <i>Infect. Immun.</i> , 56:1807-1813, 1988.

25326162.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

UTSB:721US

Serial No.

10/620,049

List of Patents and Publications for Applicant's

Applicant

Barrett R. Harvey *et al.*

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

July 15, 2003

Group:

1653

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>MS</i>	C22	Maynard <i>et al.</i> , "Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity," <i>Nat. Biotechnol.</i> , 20:597-601, 2002.
	C23	Mourez <i>et al.</i> , "Designing a polyvalent inhibitor of anthrax toxin," <i>Nature Biotechnology</i> , 19:958-961, 2001.
	C24	Pitt <i>et al.</i> , "In vitro correlate of immunity in a rabbit model of inhalational anthrax," <i>Vaccine</i> , 19:4768-4773, 2001.
	C25	Sellman <i>et al.</i> , "Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax," <i>Science</i> , 292:695-697, 2001.
	C26	Singh <i>et al.</i> , "A dominant negative mutant of <i>Bacillus anthracis</i> protective antigen inhibits anthrax toxin in vivo," <i>J. of Biol. Chem.</i> , 276:22090-22094, 2001.
	C27	Turnbill <i>et al.</i> , "Antibodies to Anthrax Toxin in Humans and Guinea Pigs and Their Relevance to Protective Immunity," Abstract, <i>Med. Microbiol. Immunol.</i> , 177:293-303, 1988.
	C28	U.S. Patent Application Serial Number 10/288,269, filed November 5, 2002 (UTSB:720US).
<i>✓</i>	C29	Wittrup, "The single cell as a microplate well," <i>Nat. Biotechnol.</i> , 18:1039-1040, 2000.

25326162.1

EXAMINER:

DATE CONSIDERED:

6/17/04

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)